Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta
|ClinicalTrials.gov Identifier: NCT00978952|
Recruitment Status : Completed
First Posted : September 17, 2009
Last Update Posted : July 2, 2017
|Condition or disease||Intervention/treatment|
|Coarctation of the Aorta||Device: Large Diameter Advanta™ V12 Covered Stent|
The performance metric for comparison is based on data from the Congenital Cardiovascular Interventional Study Consortium (CCISC) as reported by Golden and Hellenbrand . The CCISC experience from 1989 to 2005 shows a true procedural success rate of 98.6%.
The patient population will be subjects with coarctation of the aorta. A total of 70 subjects, children, adolescents and adults, will be enrolled at up to 15 study sites. Baseline clinical and angiographic assessment will determine the subject's eligibility for enrollment in the study. Subjects will continue in the study for long term annual follow-up through 3, 4, and 5 years.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||70 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Large Diameter Advanta™ V12 Covered Stent Trial for Coarctation of the Aorta|
|Study Start Date :||September 2009|
|Primary Completion Date :||May 2013|
|Study Completion Date :||April 2017|
Experimental: Investigational Group
Use of Large Diameter Advanta™ V12 Covered Stent.
Device: Large Diameter Advanta™ V12 Covered Stent
- Primary Efficacy [ Time Frame: 12 month ]The mean difference between Diastolic Velocity (DV)/Systolic Velocity(SV) pre and post procedure (i.e. pre procedure DV/SV - post procedure DV/SV) minus the difference between 12 month and post procedure (i.e. 12 month DV/SV - post procedure DV/SV).
- Primary Safety [ Time Frame: 30 days of procedure ]30 day morbidity rate of Major Adverse Events (MAE)and Major Adverse Vascular Events (MAVE)
- Secondary Safety [ Time Frame: procedural (time zero) ]Device success, defined as the successful delivery and deployment of the study stent and intact retrieval of the delivery system.
- Secondary Safety [ Time Frame: 12 month ]No post procedural stent migration, where migration is defined as displacement of the stent >20mm from an established anatomical landmark verified during deployment.
- Secondary Safety [ Time Frame: 12 months ]Major Adverse Events (MAE)and Major Adverse Vascular Events (MAVE)
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00978952
|The Children's Hospital at Westmead|
|Sydney, Australia, 2145|
|Instituto Dante Pazzanese de Cardiologia|
|Sao Paulo, Brazil, 04012-180|
|Hospital for Sick Children Labatt Family Heart Centre|
|Toronto, Ontario, Canada, M5G 1X8|
|Heart Institute Berlin|
|Frankfurt, Germany, 60389|
|Asklepios Klinik Sankt Augustin|
|Sankt Augustin, Germany, 53757|
|Schneider Children's Medical Center|
|Petach Tikva, Israel|
|San Donato Hospital|
|Bristol Royal Hospital for Children and Bristol Royal Infirmary|
|Bristol, United Kingdom, BS2 8BJ|
|Principal Investigator:||Elchanan Bruckheimer, MD||Schneider Children's Medical Center, Israel|